美国食品和药物管理局批准LumryzTM用于治疗7岁以上儿童的精神麻醉症,扩大了治疗选择. FDA approves Lumryz™ for treating narcolepsy in children aged 7+, expanding treatment options.
FDA 已批准 Lumryz™（羟丁酸钠）缓释口服混悬液用于治疗 7 岁及以上发作性睡病儿童的猝倒和白天过度嗜睡。 The FDA has approved Lumryz™ (sodium oxybate) extended-release oral suspension for treating cataplexy and excessive daytime sleepiness in children aged 7 and older with narcolepsy. 该决定以前只为成年人批准,扩大了儿科病人的治疗选择,这些病人占接受氧酸盐的精神病患者的5%。 Previously approved only for adults, this decision expands treatment options for pediatric patients, who make up 5% of the narcolepsy population receiving oxybate. Lumryz是一种受管制物质,由于CNS抑郁的风险和滥用的可能性。 Lumryz is a controlled substance due to risks of CNS depression and potential for misuse. 儿童的不良反应包括恶心和头晕。 Adverse reactions in children include nausea and dizziness.